AIX 9.01 ▲0.33% ALU 0.88 ▼-2.22% DN1 99.70 ▼-0.09% EMUCA 0.89 KIT 1.90 ▲0.00% KKC 2.11 ▲0.00% LF1 1.92 ▲0.79% MBG 0.14 ▲0.00% MRE 1.88 ▼-0.53% PCI 1.09 ▼-0.91% PCX 1.99 ▼-0.75% RF1 3.52 ▼-0.28% SET 2.14 ▼-0.47% TET 0.22 ▼-2.22% WMX 1.69 ▼-1.17% BST 0.30 ▲3.45% CTS 0.56 ▲1.82% EFR 0.00 ▲0.00% AIX 9.01 ▲0.33% ALU 0.88 ▼-2.22% DN1 99.70 ▼-0.09% EMUCA 0.89 KIT 1.90 ▲0.00% KKC 2.11 ▲0.00% LF1 1.92 ▲0.79% MBG 0.14 ▲0.00% MRE 1.88 ▼-0.53% PCI 1.09 ▼-0.91% PCX 1.99 ▼-0.75% RF1 3.52 ▼-0.28% SET 2.14 ▼-0.47% TET 0.22 ▼-2.22% WMX 1.69 ▼-1.17% BST 0.30 ▲3.45% CTS 0.56 ▲1.82% EFR 0.00 ▲0.00%

PNV PolyNovo Limited

Healthcare · Medical Devices · website · 301 employees
$0.88
52wk 0.81 – 1.67
Overall
Value
Growth
Health
Quality
Momentum
Dividend
Price
About PolyNovo Limited

PolyNovo Limited designs, manufactures, and sells biodegradable medical devices in Australia, New Zealand, the United States, the United Kingdom, Ireland, Singapore, India, and Hong Kong. The company offers NovoSorb Biodegradable Temporising Matrix, a dermal matrix for the regeneration of the dermis when lost through extensive surgery, trauma, or burn. It is also developing hernia devices for hernia repair and solution for ventral hernia and complex abdominal wall reconstruction; Beta Cell implant, a novel intracutaneous ectopic pancreas to treat type 1 diabetes; NovoSorb MTX for single stage grafting in burns, chronic, and surgical wounds; and plastics and reconstructive device products. The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.

Fundamental trends
Financial statements
Loading…
Key metrics
Market cap
$604.49M
P/E (trailing)
87.50
P/E (forward)
40.21
EPS (trailing)
0.01
Dividend yield
Payout ratio
0.0%
Beta
1.35
EV / EBITDA
88.24
Price / Book
7.29
ROE
12.5%
Operating margin
3.0%
Net margin
7.1%
Total cash
$29.26M
Total debt
$18.19M
Current ratio
3.04
Debt / Equity
0.22
Free cash flow
$-6.94M
Avg volume
3.00M
Latest annual results (FY ending 30 Jun 2025)
  • Revenue$127.24M
  • Gross profit$122.05M
  • Operating income$4.48M
  • Net income$13.21M
  • Diluted EPS0.02
  • Free cash flow-$10.78M
  • Net debt-$16.40M
Sector peers (Healthcare)
TickerMkt cap P/EScore
CSL $59.53B 14.0
RMD $43.89B 20.4
SIG $34.28B 59.4
FPH $20.25B 52.2
PME $17.21B 73.5
SHL $10.79B 19.7
RHC $10.13B 34.8
COH $7.90B 22.9